Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026

Deferred revenue of $0 in Q2 FY2026

Q2 FY2026 deferred revenue was $0.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$450K— YoY
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
450K USD
Year-over-year change
—

Deferred Revenue vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Deferred revenue amounts to 0.0% of total assets for ATTO, versus a peer median of 0.0%.
ATTO Competitors
Deferred Revenue for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$6.67M USD——1.2%
ACRSAclaris Therapeutics, Inc.Mar 2026$3.97M USD——2.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€1.69M EUR——1.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$167K USD+1.8%—0.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$0 USD——0.0%
ORKAOruka Therapeutics, Inc.Sep 2026$0 USD——0.0%
ANABAnaptysBio, Inc.Mar 2026$0 USD-100.0%—0.0%
MLTXMoonLake ImmunotherapeuticsMar 2026$0 USD——0.0%
EVMNEvommune, Inc.Mar 2026$0 USD——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 USD——0.0%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
Peer median (excluding ATTO) —-49.1%—0.0%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.